Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (New York)

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque,K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, 2015, Poster […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (New York)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, […]

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers. Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. Proceedings of the 106th Annual Meeting of the American Association for Cancer […]

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors. Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; […]

Karus Therapeutics presenting at Sachs Immuno-oncology: BD&L and Investment Forum

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer and inflammatory disease, has announced that it will be presenting at Sachs Immuno-oncology: BD&L and Investment Forum, Chicago, USA, 29th May 2015. Stephen Shuttleworth, Karus’s CSO, will present and CEO Simon Kerry will also be attending the conference. For more […]

Karus Therapeutics presenting at BioTrinity 2015

Simon Kerry, CEO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting at BioTrinity 2015, 11-13 May 2015 in Oxford, UK. For more information on Karus’s presentations or for media enquiries, please contact karus@instinctif.com.

Karus Therapeutics presenting at AACR Annual Meeting 2015

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in Philadelphia, 18–22 April 2015. Stephen Shuttleworth, Karus’s CSO, will present the posters describing the company’s pre-clinical cancer programmes.  The title of […]